Nine Month Isoniazid versus Three Month Isoniazid plus Rifapentine for Treatment of Tuberculosis Infection in Rheumatic Patients: a Randomized Controlled Trial

INTERVENTION: INH (9m) group:oral isoniazid for 9 months;INH+RFT (3m) group:oral isoniazid and rifapentine for 3 months; CONDITION: tuberculosis infection of patients with rheumatic diseases PRIMARY OUTCOME: Incidence of active tuberculosis;Drug discontinuation rate due to serious adverse events or tuberculosis activity; SECONDARY OUTCOME: Incidence of tolerable adverse events;Drug compliance; INCLUSION CRITERIA: 1. Aged between 18 and 70 years old; 2. Diagnosed with rheumatic diseases including systemic lupus erythematosus, Takayasu arteritis, Behcet's disease and primary Sjogren's syndrome; 3. No biologic agents used at present; 4. Using hormones or immunosuppressant at present (if either of the requirements below is met): 1) Hormone dosage (equivalent of Prednisone dosage)=15mg; 2) Using any of the following immunosupressants: methotrexate, cyclophosphamide, mycophenolate mofetil, cyclosporine A, azathioprine, tacrolimus, leflunomide, iguratimod, thalidomide and tripterygium glycosides; 5. T‐SPOT.TB =24 SFCs/106 PBMC.